607 related articles for article (PubMed ID: 30306365)
1. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
3. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
[TBL] [Abstract][Full Text] [Related]
4. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
Qiu M; Glass Z; Xu Q
Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
[TBL] [Abstract][Full Text] [Related]
5. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
[TBL] [Abstract][Full Text] [Related]
6. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
7. The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
Wilson RC; Gilbert LA
ACS Chem Biol; 2018 Feb; 13(2):376-382. PubMed ID: 29019396
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
10. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
12. Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing.
Naeem M; Hoque MZ; Ovais M; Basheer C; Ahmad I
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681959
[TBL] [Abstract][Full Text] [Related]
13. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
14. Progress of delivery methods for CRISPR-Cas9.
Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
[TBL] [Abstract][Full Text] [Related]
15. Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing.
Xiu K; Saunders L; Wen L; Ruan J; Dong R; Song J; Yang D; Zhang J; Xu J; Chen YE; Ma PX
Cells; 2022 Dec; 12(1):. PubMed ID: 36611948
[TBL] [Abstract][Full Text] [Related]
16. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
Tang H; Zhao X; Jiang X
Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
18. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
[TBL] [Abstract][Full Text] [Related]
19. Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications.
Zheng Q; Wang W; Zhou Y; Mo J; Chang X; Zha Z; Zha L
Biomater Sci; 2023 Aug; 11(16):5361-5389. PubMed ID: 37381725
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
